CB2 Insights to take over clinical cannabis care at six New Jersey facilities

CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF) bolstered its clinical division Tuesday by taking over the assets of New Jersey Alternative Medicine.

The Toronto-based company will assume all clinical care of the 15,000 patients at NJAM’s 6 facilities in the state. The clinics are part of the Canna Care Docs brand, which is the largest multi-state medical cannabis clinic operator in the US.

New Jersey marks the third US state CB2 has expanded into since April, following the acquisitions of Relaxed Clarity and MedEval Clinics in Colorado and Arizona. All told, the company will operate about 40 medical cannabis evaluation and education facilities in the US, in addition to telemedicine services to patients in Maine and New York.

READ: CB2 Insights strengthens board with new member and appoints chairman

“New Jersey is an exciting market for CB2; with over 50,000 active patients and growing across the state, and further advancements to the medical cannabis program to expand on indications and patient access,” CEO Prad Sekar said. “NJAM, who has already captured care of more than 25% of the market, will provide CB2 with a solid base of patients and revenue to capitalize on the growth this state will continue to see.”

CB2 Insights is a data-driven company with the aim of folding cannabis treatment into the traditional health care sector by collecting information and offering predictive point-of-care analysis.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors